Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) deliver high
response rates with relatively modest toxicity in patients with advanced EGFR-mutated non …

Molecular target therapies using first-generation, reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …

Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …

First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs),
gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients …